SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
March 7, 2007
CardioVascular BioTherapeutics, Inc.
(Exact name of registrant as specified in its charter)
| | | | |
Delaware | | 000-51172 | | 33-0795984 |
(State or other jurisdiction of incorporation) | | (Commission File Number) | | (IRS Employer Identification No.) |
1635 Village Center Circle, Suite 250
Las Vegas, Nevada
89134
(Address of Principal Executive Offices)
(Zip Code)
Registrant's telephone number, including area code:702-839-7200
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 7.01. Regulation FD Disclosure.
| | | CardioVascular BioTherapeutics, Inc. (the “Company”), in connection with its efforts to list its shares of common stock on the Alternative Investments Market of the London Stock Exchange (“AIM”), will distribute a document describing the Company’s business to prospective foreign investors, which include institutions, persons who fall within the exemptions contained in Articles 19 and 49 of the Financial Services and Markets Act 2000 Order 2005, and persons to whom distribution may otherwise lawfully be made, (the “Pathfinder”) on or about the date hereof. A true and correct copy of the entire Pathfinder document, as printed, is furnished as Exhibit 99.1. |
| | | The information in Item 7.01 of this Pathfinder document, including Exhibit 99.1, is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section. The information in Item 7.01 of this Current Report, including Exhibit 99.1, shall not be incorporated by reference into any registration statement or other document filed pursuant to the Securities Act of 1933, as amended, or the Exchange Act. |
Item 9.01 Financial Statements and Exhibits.
(c) Exhibits
| | 99.1 | Pathfinder as printed on or about March 3, 2007. |
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this review to be signed on its behalf by the undersigned hereunto duly authorized.
| | | | | | | | |
| | | | CARDIOVASCULAR BIOTHERAPEUTICS, INC. |
| | | |
| Date: March 7, 2007 | | | | By: | | /s/ Mickael A. Flaa |
| | | | | | | | Mickael A. Flaa |
| | | | | | | | Chief Financial Officer |
3
EXHIBIT INDEX
99.1 Pathfinder as printed on or about March 3, 2007
4
